Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose subcutaneous REGN668 in adults with moderate-to-severe atopic dermatitis
2011-003836-29Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing REGN668/SAR231893 active treatment with Placebo (2 arms). Primary endpoint: Percent change in EASI score from baseline to week 12. Started Dec 2011; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2011-003836-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003836-29.